Next-generation sequencing based genetic testing requires proof-of-concept validation with established performance metrics before introducing into the clinical laboratory. The performance metrics evaluated to establish the analytical validity of test results include accuracy, precision, analytical sensitivity, analytical specificity. Precision is typically determined by assessing repeatability and reproducibility. Repeatability (within-run precision) means testing the same sample repeatedly under the same operating conditions (the same people, same time, same place etc.) to evaluate the closeness of agreement between repeated tests. Reproducibility (between-run precision) means the closeness of agreement between the results of measurements when operating conditions are varied(different people, different time etc.). As bioinformatics analysis pipeline is a key component of next-generation sequencing, several guidelines recommended that the bioinformatics analysis pipeline should also be validated. My question is how to evaluate the precision (repeatability and reproducibility) of a bioinformatics analysis pipeline? Or, do I need to evaluate the precision (repeatability and reproducibility) of a bioinformatics analysis pipeline?
Izy | You might want to make your question clear. As phrased, your post does not contain a question. I think you are wondering what, after clinically important SNVs are discovered/approved, needs to be done to be sure of an individual's status for that SNV. But I am unsure.
Thanks, jnf3769. I have revised my question. I just want to know "How to evaluate the precision (repeatability and reproducibility) of a bioinformatics analysis pipeline? Or, do I need to evaluate the precision (repeatability and reproducibility) of a bioinformatics analysis pipeline?"